Magenta Therapeutics Inc (NASDAQ:MGTA) insider Michael P. Cooke sold 7,500 shares of the business’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $13.42, for a total transaction of $100,650.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Shares of MGTA opened at $13.18 on Friday. The stock has a market capitalization of $471.15 million and a price-to-earnings ratio of -4.21. Magenta Therapeutics Inc has a 1-year low of $5.31 and a 1-year high of $21.00. The firm’s fifty day moving average is $13.88.
Magenta Therapeutics (NASDAQ:MGTA) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.11. As a group, equities research analysts anticipate that Magenta Therapeutics Inc will post -2.03 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently bought and sold shares of MGTA. New York State Common Retirement Fund acquired a new position in Magenta Therapeutics during the fourth quarter valued at $27,000. BNP Paribas Arbitrage SA acquired a new position in Magenta Therapeutics during the first quarter valued at $50,000. Bank of New York Mellon Corp acquired a new position in Magenta Therapeutics during the fourth quarter valued at $90,000. Two Sigma Investments LP acquired a new position in Magenta Therapeutics during the fourth quarter valued at $104,000. Finally, Geode Capital Management LLC lifted its position in Magenta Therapeutics by 42.9% during the fourth quarter. Geode Capital Management LLC now owns 21,739 shares of the company’s stock valued at $123,000 after purchasing an additional 6,525 shares during the period. Institutional investors own 63.62% of the company’s stock.
Magenta Therapeutics Company Profile
Magenta Therapeutics, Inc, a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases.
Read More: Arbitrage
Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.